Innoviva (INVA) Q2 2026: higher revenue, investment losses drive quarterly net loss
Rhea-AI Filing Summary
Innoviva, Inc. reported second quarter 2026 results featuring higher revenue but a net loss driven by investment fair value movements. Total revenue for the quarter ended June 30, 2026 was $119.6 million, with royalty revenue, net of capitalized fee amortization, of $56.3 million, net product sales of $51.8 million, and license and other revenue of $11.5 million. Income from operations was $50.9 million, but large negative changes in the fair values of equity method investments of $(131.8) million and equity and long-term investments of $(29.2) million led to a net loss of $(83.4) million, compared with net income of $63.7 million a year earlier.
For the first six months of 2026, total revenue was $217.6 million and net income was $103.2 million, indicating strong year-to-date profitability despite the second-quarter loss. Cash and cash equivalents were $570.4 million as of June 30, 2026, supported by $87.3 million of net cash provided by operating activities in the first half. The Innoviva Specialty Therapeutics platform generated U.S. net product sales of $36.6 million in the quarter, representing 26% year-over-year growth, and management stated it remains on track to achieve at least $150 million in IST U.S. net product sales in 2026. The company also highlighted a commercialization and licensing agreement with Dr. Reddy’s Laboratories for XACDURO in emerging markets and the launch of Nortiva Bio, a wholly owned strategic healthcare asset focused on extended-release oral drug delivery.
Positive
- Total revenue grew to $119.6 million in Q2 2026 from $100.3 million a year earlier, and income from operations increased to $50.9 million, while first-half 2026 net income rose to $103.2 million from $17.1 million.
- Liquidity remains strong with cash and cash equivalents of $570.4 million at June 30, 2026 and $87.3 million in net cash provided by operating activities during the first six months of 2026.
Negative
- Q2 2026 swung to a net loss of $(83.4) million versus net income of $63.7 million in Q2 2025, mainly due to negative fair value changes of $(131.8) million in equity method investments and $(29.2) million in equity and long-term investments.
Filing Explained
The filing adds evidence of share-repurchase cash use, but does not quantify the repurchases or resulting change in common shares.
Form 8-K reports a specified material event, and this filing furnishes the company’s August 5 earnings release under Item 2.02 rather than presenting it as information deemed filed under the Exchange Act.
The release says Innoviva continued activity under its share-repurchase program, while the six-month cash-flow statement reports
The balance sheet provides additional context for the quarter’s investment-related result: equity-method and equity and long-term investments totaled
The relevant checkpoint is the six-month financing-activities line in the
8-K Event Classification
Key Figures
Key Terms
royalty revenue, net financial
equity method investments financial
convertible senior notes financial
Net product sales financial
forward-looking statements regulatory
Earnings Snapshot
Management stated it remains on track to achieve at least $150 million in IST U.S. net product sales in 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Innoviva (INVA) perform financially in Q2 2026?
What were Innoviva (INVA)'s year-to-date 2026 results?
How did Innoviva's IST segment perform in Q2 2026?
What caused Innoviva (INVA)'s Q2 2026 net loss?
What is Innoviva (INVA)'s cash and balance sheet position as of June 30, 2026?
What outlook did Innoviva (INVA) provide for IST in 2026?
What strategic actions did Innoviva (INVA) highlight for Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition |
On August 5, 2026, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Press Release dated August 5, 2026 | |
| 104 | Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document) | |
- 2 -
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INNOVIVA, INC. | ||||||
| Date: August 5, 2026 | By: | /s/ Pavel Raifeld | ||||
| Pavel Raifeld | ||||||
| Chief Executive Officer | ||||||
- 3 -
Exhibit 99.1
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth
Royalties portfolio generated $59.8 million in second quarter revenue
Launch of wholly-owned Strategic Healthcare Asset, Nortiva Bio, focused on novel extended-release drug delivery technology
BURLINGAME, Calif. – Aug 5, 2026 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2026, and highlighted select corporate progress and achievements.
“Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial momentum at IST, which achieved 46% year-over-year net product sales growth, including 26% growth in U.S. sales. We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution,” said Pavel Raifeld, Chief Executive Officer of Innoviva.
“Recently, we also advanced several growth opportunities. This quarter, we announced a commercialization and licensing agreement with Dr. Reddy’s Laboratories, expanding access to our top-performing antibiotic, XACDURO, in emerging markets. Additionally, we launched Nortiva Bio, a novel platform for long-acting oral medicine delivery, with large upside potential.”
“Overall, we have been pleased with progress across our healthcare asset portfolio, despite market volatility. Our continued activity under the share repurchase program reflects our sustained conviction in the long-term prospects of our diversified business model — one that combines durable cash generation, strong operating revenue growth, and value creation in high-potential strategic opportunities.”
Financial Highlights for the Second Quarter of 2026
| • | Total revenue: $119.6 million, representing 19% year-on-year growth compared to $100.3 million for the second quarter of 2025. |
| • |
|
| • | Net product sales: $51.8 million ($36.6 million U.S. and $15.2 million ex-U.S.), representing 46% growth compared to $35.5 million in the second quarter of 2025. U.S. net product sales primarily consisted of $21.0 million from GIAPREZA®, $12.0 million from XACDURO®, and $3.3 million from XERAVA®. |
| • | Income from operations: $50.9 million, compared to $48.8 million for the second quarter of 2025, reflecting higher net product sales and continued operating discipline. |
| • | Equity and long-term investments: net unfavorable changes in fair value of equity and long-term investments totaled $161.0 million, primarily attributable to a lower share price of Armata Pharmaceuticals. Innoviva’s strategic healthcare investments were valued at $669.5 million as of June 30, 2026, and consisted of $457.7 million in Armata Pharmaceuticals, $177.3 million in other strategic equity and convertible debt, and $34.5 million held by ISP Fund. |
| • | Net income: net loss of $83.4 million, or $1.14 basic loss per share, driven primarily by decrease in fair value of equity and long-term investments. |
| • | Cash and cash equivalents: Totaled $570.4 million. Royalty and net product sales receivables totaled $110.6 million as of June 30, 2026, a 25% year-on-year increase compared to $88.3 million for the second quarter of 2025. |
Key Business and R&D Highlights
| • | XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use: a targeted antibacterial treatment for patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. |
| • | During the second quarter, IST entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® in South and Central America, the Caribbean, Russia and Commonwealth of Independent States countries. |
| • | Strategic Healthcare Assets |
| • | During the second quarter, Innoviva launched Nortiva Bio (a wholly owned subsidiary), to advance the proprietary LYNX™ long-acting oral drug delivery platform. The LYNX platform is designed to transform daily oral medicines into less frequent dosing regimens, including once-weekly or once-monthly therapies. The platform is designed to improve patient adherence, stabilize drug exposure, and enhance clinical and commercial value by enabling less frequent oral dosing. |
| • | Nortiva is advancing a lead once-monthly oral drug therapy development program (via support from the Gates Foundation) and building an external partnering pipeline to enable the development of long-acting oral versions of branded and generic therapies. |
| • | Capital Allocation |
| • | During the second quarter of 2026, Innoviva repurchased 1,403,247 shares for $31.4 million under its $125 million share repurchase program. Since inception, and through the end of the second quarter, the Company has repurchased 2,602,168 shares for $56.4 million, reflecting the Company’s continued confidence in its intrinsic value and long-term outlook. |
| • | During the second quarter of 2026, Innoviva continued to support companies in its strategic healthcare asset portfolio with $55.0 million aggregate capital commitment. |
- 2 -
About Innoviva
Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA® (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus, XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and NUZOLVENCE® (zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg. For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica Ltd, Allschwil.
Forward Looking Statements
This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA®, XACDURO®, ZEVTERA® and NUZOLVENCE® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the development of the LYNX® platform; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital
- 3 -
returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
- 4 -
INNOVIVA, INC.
Condensed Consolidated Statements of Income
(in thousands, except per share data)
(Unaudited)
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: |
||||||||||||||||
| Royalty revenue, net (1) |
$ | 56,334 | $ | 63,880 | $ | 111,501 | $ | 121,687 | ||||||||
| Net product sales |
51,771 | 35,493 | 93,142 | 65,772 | ||||||||||||
| License and other revenue |
11,486 | 910 | 12,942 | 1,456 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenue |
119,591 | 100,283 | 217,585 | 188,915 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of products sold (inclusive of amortization of inventory fair value adjustments) |
22,349 | 10,590 | 37,956 | 19,432 | ||||||||||||
| Amortization of acquired intangible assets |
6,626 | 6,547 | 13,180 | 13,022 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross profit |
90,616 | 83,146 | 166,449 | 156,461 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating expenses: |
||||||||||||||||
| Selling, general and administrative |
34,571 | 26,412 | 67,009 | 53,903 | ||||||||||||
| Research and development |
5,190 | 7,983 | 10,431 | 12,379 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
39,761 | 34,395 | 77,440 | 66,282 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income from operations |
50,855 | 48,751 | 89,009 | 90,179 | ||||||||||||
| Changes in fair values of equity method investments, net |
(131,834 | ) | 13,082 | 25,816 | (467 | ) | ||||||||||
| Changes in fair values of equity and long-term investments, net |
(29,153 | ) | 11,280 | 4,422 | (54,019 | ) | ||||||||||
| Interest and dividend income |
7,599 | 4,925 | 18,586 | 9,463 | ||||||||||||
| Interest expense |
(5,472 | ) | (4,663 | ) | (10,909 | ) | (9,374 | ) | ||||||||
| Other expense, net |
(15 | ) | (777 | ) | (381 | ) | (1,773 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income (loss) before income taxes |
(108,020 | ) | 72,598 | 126,543 | 34,009 | |||||||||||
| Income tax benefit (expense) |
24,600 | (8,910 | ) | (23,368 | ) | (16,905 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
$ | (83,420 | ) | $ | 63,688 | $ | 103,175 | $ | 17,104 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) per share: |
||||||||||||||||
| Basic |
$ | (1.14 | ) | $ | 1.01 | $ | 1.40 | $ | 0.27 | |||||||
| Diluted |
$ | (1.14 | ) | $ | 0.77 | $ | 1.25 | $ | 0.24 | |||||||
| Shares used to compute net income (loss) per share: |
||||||||||||||||
| Basic |
73,421 | 62,865 | 73,789 | 62,787 | ||||||||||||
| Diluted |
73,421 | 84,452 | 84,529 | 84,342 | ||||||||||||
| (1) Total net revenue is comprised of the following (in thousands): |
| |||||||||||||||
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Royalties |
$ | 59,790 | $ | 67,336 | $ | 118,413 | $ | 128,599 | ||||||||
| Amortization of capitalized fees |
(3,456 | ) | (3,456 | ) | (6,912 | ) | (6,912 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Royalty revenue, net |
$ | 56,334 | $ | 63,880 | $ | 111,501 | # | $ | 121,687 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
- 5 -
INNOVIVA, INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| June 30, 2026 |
December 31, 2025 |
|||||||
| Assets |
||||||||
| Cash and cash equivalents |
$ | 570,388 | $ | 550,941 | ||||
| Royalty and product sale receivables |
110,616 | 93,317 | ||||||
| Inventory |
38,968 | 39,172 | ||||||
| Prepaid expense and other current assets |
24,726 | 28,358 | ||||||
| Current portion of ISP Fund investments |
8,668 | 15,727 | ||||||
| Property and equipment, net |
2,133 | 1,555 | ||||||
| Equity method and equity and long-term investments |
660,850 | 598,223 | ||||||
| Capitalized fees |
49,226 | 56,138 | ||||||
| Right-of-use assets |
10,377 | 10,929 | ||||||
| Goodwill |
17,905 | 17,905 | ||||||
| Intangible assets |
168,976 | 182,156 | ||||||
| Other assets |
39,894 | 40,744 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 1,702,727 | $ | 1,635,165 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ equity |
||||||||
| Other current liabilities |
$ | 39,431 | $ | 43,808 | ||||
| Accrued interest payable |
1,618 | 1,618 | ||||||
| Deferred revenue |
6,015 | 4,270 | ||||||
| Convertible senior notes, due 2028, net |
258,454 | 257,731 | ||||||
| Deferred tax liabilities, net |
36,739 | 31,793 | ||||||
| Income tax payable, long term |
59,932 | 57,013 | ||||||
| Other long term liabilities |
67,276 | 66,091 | ||||||
| Stockholders’ equity |
1,233,262 | 1,172,841 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 1,702,727 | $ | 1,635,165 | ||||
|
|
|
|
|
|||||
- 6 -
INNOVIVA, INC.
Cash Flows Summary
(in thousands)
(unaudited)
| Six Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash provided by operating activities |
$ | 87,254 | $ | 92,690 | ||||
| Net cash used in investing activities |
(18,256 | ) | (1,552 | ) | ||||
| Net cash provided by (used in) financing activities |
(49,551 | ) | 1,430 | |||||
|
|
|
|
|
|||||
| Net change |
$ | 19,447 | $ | 92,568 | ||||
| Cash and cash equivalents at beginning of period |
550,941 | 304,964 | ||||||
|
|
|
|
|
|||||
| Cash and cash equivalents at end of period |
$ | 570,388 | $ | 397,532 | ||||
|
|
|
|
|
|||||
- 7 -
Investors and media contact
Irwin Tendler
Head of Investor Relations
Executive Director, Corporate Development
investors.relations@inva.com
- 8 -